HIV / AIDS · Chapter 2
Antidepressants in HIV
Depression is the most common psychiatric comorbidity in HIV — and because it drives non-adherence, treating it protects the regimen, not just the mood. Which antidepressants are safe with antiretrovirals, which the regimen bends, and the two agents to reach for first.
Bottom Line Up Front
The 30-second version
- Treating depression is an adherence intervention. Depression is the most common psychiatric comorbidity in HIV and a well-established driver of missed doses and worse virologic outcomes. Under-treating it out of interaction fear costs more than the interaction would.
- Two agents lead: sertraline and escitalopram. Both are well-studied in HIV and have minimal effect on antiretroviral levels, so they rarely threaten the regimen. Start low, titrate to response.
- The regimen still bends the dose. Boosters (ritonavir, cobicistat) tend to raise antidepressant levels; efavirenz and the NNRTIs lower them (sertraline AUC −39%, bupropion roughly −55% on efavirenz); modern integrase anchors leave SSRI levels essentially alone.
- Two hard stops. St John's wort is effectively contraindicated — it strips antiretroviral levels and can cause virologic failure. And trazodone and the TCAs stack QTc and sedation exactly when a booster is already raising their concentration.
Why This Is a Prescribing Priority, Not a Deferral
Depression runs several times more common in people living with HIV than in the general population, and it is not a benign comorbidity: depressive illness is one of the most consistent predictors of antiretroviral non-adherence, and non-adherence is what drives detectable viral load, resistance, and disease progression. The clinical logic is therefore inverted from how interaction anxiety usually plays out — the risk of not treating the depression (a patient who stops taking ART) generally outweighs the risk of a managed drug interaction.
That reframes the whole chapter. The goal is not to find the one antidepressant with zero interactions and use only that; it's to treat the depression effectively while accounting for what the regimen does to the drug. Most antidepressants can be used safely in HIV with the right agent choice and dose awareness. The job is to pick well and dose to the regimen bucket — not to withhold.
First-Line: The SSRIs Built for This Population
SSRIs are the default class, and within it three agents stand out precisely because they do not meaningfully inhibit the CYP enzymes that antiretrovirals depend on — so they are unlikely to raise antiretroviral levels: sertraline, escitalopram, and citalopram. Sertraline is the best-studied in HIV; escitalopram has the cleanest interaction profile (no significant change when given with ritonavir).
| Agent | Effect of ART / caution | Verdict |
|---|---|---|
| Sertraline | Best-evidenced SSRI in HIV. Levels fall on some boosted PIs (AUC −49% with darunavir/ritonavir per the DHHS interaction tables) and on efavirenz (−39%); titrate to clinical response. Minimal effect on antiretroviral levels. | First-line |
| Escitalopram | Cleanest interaction profile — no significant change with ritonavir. Milder QTc signal than citalopram. Low effect on antiretroviral levels. | First-line |
| Citalopram | Also low interaction potential, but carries a dose-dependent QTc caution and a dose ceiling — watch additive QTc with QT-prolonging antiretrovirals and infection-related agents. | Good, mind QTc |
| Paroxetine | Messier: a CYP2D6 inhibitor (can raise other drugs), anticholinergic, and its level moves unpredictably by PI — AUC −39% with darunavir/ritonavir, but the direction varies with other boosters (guidelines list “↑ or ↓ possible”); efavirenz has little effect. | Not first choice |
| Fluoxetine / Fluvoxamine | Potent CYP inhibitors (fluoxetine mainly 2D6, with a long-acting active metabolite; fluvoxamine 1A2/2C19/3A4) — they can raise antiretroviral levels toward toxicity. And because ritonavir in turn raises fluoxetine and its long-lived metabolite, serotonin-syndrome cases have followed that combination. | Use with caution |
The one clear recommendation: reach for sertraline or escitalopram as the default. Start at a low dose, titrate to response, and let the regimen bucket (below) tell you whether the level is likely running high or low.
The Rest of the Toolkit
Beyond the SSRIs, several agents earn a place — sometimes because a “side effect” is exactly what a given HIV patient needs.
| Agent | Effect of ART / role | Verdict |
|---|---|---|
| Bupropion | The paradox agent: ritonavir and efavirenz lower bupropion (CYP2B6 induction; efavirenz roughly −55%), so it may need a higher dose — but never exceed the max, and respect the seizure threshold in a neurologically vulnerable population. Not lowered by cobicistat. Useful for fatigue, apathy, and smoking cessation. | Good, dose-aware |
| Mirtazapine | A CYP3A4 substrate, so boosters raise its level and its sedation — but the sedation, appetite stimulation, and anti-nausea effect are a feature in HIV-related weight loss, poor appetite, and insomnia. Start low on a boosted regimen. | Useful niche |
| SNRIs (venlafaxine, duloxetine, desvenlafaxine) | Effective; levels generally rise with boosters — though duloxetine's direction is less predictable with ritonavir-boosted regimens (↑ or ↓), while it rises with cobicistat. Duloxetine adds a hepatotoxicity caution that matters in HIV/HCV co-infection or liver disease — but both duloxetine and venlafaxine also help HIV distal neuropathic pain, doing two jobs at once. | Reasonable, watch liver / BP |
| Tricyclics (TCAs) | Levels climb with boosters and PIs; anticholinergic burden, QTc, and overdose lethality make them a poor first choice. Low-dose nortriptyline retains a role for neuropathic pain — but with ECG awareness. | Avoid as first-line |
The Interaction Traps
Three patterns cause most of the trouble, and each has a clean rule.
Stop / caution
- St John's wort — effectively contraindicated. It's a potent CYP3A4 and P-glycoprotein inducer: it dropped indinavir AUC by a mean of 57% and the trough by 81% (Piscitelli, Lancet 2000), and it lowers efavirenz and other antiretrovirals the same way — a direct path to subtherapeutic levels, virologic failure, and resistance. Patients self-medicate with it for low mood, so ask by name and swap it for a regulated antidepressant.
- Trazodone with a booster. Ritonavir markedly raises trazodone exposure (AUC reported up to roughly +240%), halving its clearance and producing sedation, dizziness, hypotension, and even syncope — plus additive QTc. If you use it as a hypnotic on a boosted regimen, use a low dose and watch closely; on a clean integrase regimen it behaves more predictably.
- Fluoxetine and fluvoxamine as enzyme inhibitors. These raise the antiretroviral, not just the mood — a reverse-direction interaction that can push PI levels toward toxicity. Prefer sertraline or escitalopram, which don't do this.
Notice the pattern: the SSRIs to avoid are avoided because they act back on the regimen, and the sedating agents (trazodone, TCAs) are the ones that stack QTc and sedation when a booster is already raising their concentration. The clean agents are clean in both directions.
Selecting by Regimen Bucket
Carry the framework's three buckets straight into the antidepressant decision. The bucket tells you which way the level moves and what to pre-empt.
| Regimen bucket | What happens to the antidepressant | What to do |
|---|---|---|
| Booster (/r, /c) | Most antidepressant levels rise — especially trazodone, TCAs, mirtazapine. Bupropion is the exception (falls with ritonavir, unchanged with cobicistat). | Start low; avoid trazodone/TCA where possible; mind QTc (citalopram, TCA, trazodone); prefer sertraline/escitalopram. |
| NNRTI inducer (efavirenz) | Levels fall — sertraline −39%, bupropion roughly −55% — risking apparent non-response. And efavirenz itself can cause depression. | Titrate up to clinical effect; before calling it treatment-resistant, consider that efavirenz may be causing the depression — discuss a switch. |
| Integrase anchor (bictegravir / dolutegravir) | SSRI levels essentially unchanged; the modern low-interaction default. | Choose the antidepressant on its own merits and dose normally. Don't reflexively underdose. |
Special Situations Where the Antidepressant Does Two Jobs
- HIV distal sensory neuropathy. Duloxetine or low-dose nortriptyline treats both the mood and the pain; the renally-cleared gabapentinoids (a clean interaction profile) are the other route — covered in the mood-stabilizer and stimulant chapters.
- Wasting, poor appetite, insomnia. Mirtazapine's sedation and appetite stimulation are the point, not a nuisance — one agent for three problems.
- Efavirenz-associated depression. Vivid dreams, insomnia, low mood, and a suicidality signal can be the drug. Consider the regimen as the driver and discuss a switch before escalating antidepressants into apparent treatment resistance.
- Additive QTc. Citalopram, TCAs, and trazodone add to any QT-prolonging antiretroviral or infection agent — check an ECG when stacking, and favor escitalopram over citalopram.
The Action Ladder
Default, any regimen
Start sertraline or escitalopram, low dose, titrate to response. On an integrase anchor, dose as you would in any patient. Always ask about St John's wort and stop it.
Boosted regimen (/r or /c)
Expect higher antidepressant levels; start low. Avoid trazodone and TCAs where possible; if bupropion, remember ritonavir lowers it (cobicistat does not). Watch QTc with citalopram/TCA/trazodone.
Efavirenz / NNRTI regimen
Expect lower levels — titrate up to effect and re-check one to two weeks after any regimen change. Screen the depression itself for an efavirenz cause before declaring non-response.
Apparent treatment resistance
Before combining or augmenting: confirm adherence, re-check the regimen bucket (is an inducer stripping the level?), rule out efavirenz as the cause, and exclude an untreated medical or CNS process. The answer is often the regimen, not the antidepressant.
Clinical Pearls
Pearls
- Sertraline and escitalopram are the workhorses. Well-studied, minimal effect on antiretroviral levels, effective — the safe default in almost any regimen.
- Ask about St John's wort by name. Patients don't consider a “herbal” a drug; it can silently drop antiretroviral levels and undo the regimen. Swap it for a regulated agent.
- Fluoxetine and fluvoxamine push the wrong way. They inhibit CYP and raise the antiretroviral toward toxicity — the reverse of the usual concern. Choose an SSRI that doesn't.
- Bupropion falls on efavirenz and ritonavir. Titrate up to effect (not past the max) and mind the seizure threshold; cobicistat, lacking the induction, leaves it unchanged.
- Let the side effect work for you. Mirtazapine for wasting/insomnia; an SNRI or low-dose TCA for co-existing neuropathic pain — one drug, two targets.
- “Treatment-resistant” depression on efavirenz is often the efavirenz. Consider the regimen as the cause before stacking agents.
- On a modern integrase regimen, dose normally. SSRIs are essentially unaffected — treat the depression properly rather than reflexively underdosing.
Red Flags — Stop and Reassess
Hold and look closer
- A patient on antiretrovirals taking St John's wort (or any “natural” mood product) — stop it and check a viral load; suspect subtherapeutic antiretroviral levels.
- New agitation, tremor, clonus, or autonomic instability after adding an SSRI to a ritonavir-boosted regimen — consider serotonin syndrome from a raised SSRI level.
- Trazodone or a TCA started on a boosted regimen with a QT-prolonging co-medication — check an ECG before continuing.
- Loss of antidepressant response after an antiretroviral switch onto or off efavirenz — suspect an induction change in the level; re-titrate.
- New or worsening depression and suicidal ideation coinciding with efavirenz — treat the regimen as the likely driver and involve the HIV team.
Patient Counseling Script
Plain-language script
“Depression is common with HIV, and treating it actually helps you stay on your HIV medication, so this matters for both. I'm choosing an antidepressant that works well with your regimen — we'll start low and adjust to how you feel. Two things I need from you. First, please don't take St John's wort or any herbal mood remedy — it can quietly weaken your HIV treatment, and there are safe alternatives. Second, tell me before you start, stop, or change any medication, including your HIV drugs, because that can shift the level of this one. Give it a few weeks, keep taking your HIV medication exactly as prescribed, and if you have new restlessness, or thoughts of harming yourself, call us right away.”
EMR / Documentation Template
References
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. U.S. Department of Health and Human Services; 2025. (Antiretroviral–antidepressant interaction tables: paroxetine and sertraline AUC changes with boosted regimens.)
- National HIV Curriculum (University of Washington). Drug Interactions with Antiretroviral Medications. hiv.uw.edu; 2026. (SSRIs generally safe; integrase inhibitors do not affect SSRI levels; PIs/ritonavir/cobicistat raise TCAs and trazodone.)
- Prezista (darunavir) Prescribing Information. Janssen. (Corroborates the direction — ↓ sertraline and paroxetine with darunavir/ritonavir; specific magnitudes, sertraline AUC −49% and paroxetine −39%, are tabulated in the DHHS guidelines above.)
- Wellbutrin (bupropion) Prescribing Information. (Ritonavir and efavirenz reduce bupropion exposure via CYP2B6 induction; do not exceed maximum dose.)
- Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet. 2000;355(9203):547–548. (Indinavir AUC −57%, trough −81%.)
- Thompson A, et al. Choosing antidepressants for HIV and AIDS patients: insights on safety and side effects. (Agent-by-agent interaction review; escitalopram/ritonavir no significant effect; citalopram low interaction.)
- Clinical implications and management of drug-drug interactions between antiretroviral agents and psychotropic medications. Ment Health Clin. 2013;2(9):274. (Class-by-class psychotropic–ART interactions; serotonin-syndrome cases with fluoxetine plus ritonavir.)
Last reviewed July 2026. Sensitive-content note: references depression, suicidality, and efavirenz-associated suicidal ideation (clinical / adverse-effect context only). Part of the Psychiatry Education Forum Academy; for clinician education — it supports, and does not replace, individual clinical judgment and current local protocols.
Same logic, higher stakes: the antipsychotics.
You've seen how the regimen bends an antidepressant's level. Antipsychotics raise the ante — the same booster-driven level rises now collide with QTc and metabolic risk. The member chapters take each class the rest of the way, and behind them sits the interaction engine that powers every one of these calls.
Educational use only. Refer to the sources cited above and current prescribing information for clinical decisions. Psychiatry Education Forum and authors assume no liability for use of this material.
Responses